Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi A M, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F
Chair of Gastroenterology, University of Modena, Italy.
Dig Dis Sci. 1996 Jun;41(6):1241-7. doi: 10.1007/BF02088244.
Interferon-alpha has been widely used in chronic hepatitis C, but controlled studies with intramuscular interferon-beta are lacking. We therefore performed a prospective, double-blind, randomized study comparing intramuscular IFN-alpha and -beta in patients with chronic hepatitis C. Sixty patients were randomly assigned to receive 3 MU thrice weekly intramuscularly of either recombinant IFN-alpha or leukocyte IFN-alpha or fibroblast IFN-beta for six months. Nine of 20 patients (45.0%) in the recombinant IFN, 5/19 (26.3%) in the leukocyte IFN, and none in the IFN-beta group had a complete response during therapy (recombinant IFN vs IFN-beta: P < 0.01). Only in IFN-alpha-treated patients, was infection with a single HCV genotype (type 2a or 2b) associated with significantly better long-term outcome. IFN-alpha is useful in chronic hepatitis C while intramuscular IFN-beta interferon does not exert any beneficial effect. This is probably due to an insufficient bioavailability of IFN-beta when given intramuscularly.
α干扰素已广泛应用于慢性丙型肝炎，但缺乏关于肌肉注射β干扰素的对照研究。因此，我们进行了一项前瞻性、双盲、随机研究，比较慢性丙型肝炎患者肌肉注射α干扰素和β干扰素的疗效。60例患者被随机分为三组，分别接受每周三次、每次3 MU的重组α干扰素、白细胞α干扰素或成纤维细胞β干扰素肌肉注射，疗程6个月。重组α干扰素组20例患者中有9例（45.0%）、白细胞α干扰素组19例中有5例（26.3%）在治疗期间获得完全缓解，而β干扰素组无一例完全缓解（重组α干扰素与β干扰素比较：P<0.01）。仅在接受α干扰素治疗的患者中，感染单一HCV基因型（2a型或2b型）与显著更好的长期预后相关。α干扰素对慢性丙型肝炎有效，而肌肉注射β干扰素则无任何有益作用。这可能是由于肌肉注射时β干扰素的生物利用度不足所致。
